Enhancing AAV Capsid Titer With Precise Quantification And Validated Performance

In the rapidly evolving field of gene therapy, accurate measurement of adeno-associated viral (AAV) capsid titer is paramount for effective bioprocessing. Leveraging the benefits of an innovative Bio-Layer Interferometry (BLI) platform can streamline this critical process and help meet demand for these life-saving therapies.

Industry expert Dr. Ivan Krylov, Product Manager at Sartorius, underscores the significance of AAV titer as a vital quality attribute, noting that traditional methods such as ELISA and HPLC are often cumbersome and time-intensive, and reviews the benefits of Sartorius’ Octet® BLI platform. The Octet® AAVX Biosensors represent a breakthrough in AAV capsid quantitation, offering a rapid, label-free, and high-throughput approach that reduces analysis time from hours to just 15 minutes. This one-step process not only ensures real-time data acquisition but also maintains high specificity for various AAV serotypes, making it applicable for both purified and crude samples.

The reliability of this system has been corroborated by its strong correlation with traditional ELISA results. As the gene therapy landscape continues to expand, Sartorius is committed to evolving its technologies to meet the dynamic needs of its customers. Learn how this advancement in AAV titer determination not only aids in expediting gene therapy development but also enhances the overall quality control processes.